Medivation Nears Alzheimer’s Results
The Market Financial Breaking News Newsletter
If you are having trouble viewing this message, please go to http://community.icontact.com/p/stockshaven/newsletters/distributionlistpublic/posts/medivation-nears-alzheimers-results [1][2] Breaking News and Insider Scoops March 30, 2011 Medivation Could Double On Potentially Positive Alzheimer`s Phase III Trial Results Medivation ([3]NADSAQ:MDVN) was once a thriving biotech with some of the most promising treatments for Alzheimers, Huntington Disease and Prostate cancer.
Reaching an all-time high of $40 per share back in early 2010, the stock had investors on the edge of their seat in anticipation of what could become, but instead fell short as the HORIZON (mild-to-modarate) Alzheimers trial failed to improve the cognitive abilities in patients, which was the primary goal of the trial.
This development caused shares to immediately plunge to $12, leading many shareholders to exit their positions and move onto other opportunities. Since then, shares have quietly crept up more than 67% as a new ray of hope has emerged for its Alzheimers drug. In light of the bad news, University of Southern California Alzheimers expert Lon Schneider sees a positive amidst all the uncertainty. According to [4]Robert Langreth of Forbes, Schneider points out that while Dimebon did nothing to improve the cognitive abilities of Alzheimers patients , patients who took the drug did improve slightly over the course of the trial on something called the Neuropsychiatric Inventory. This scale measures behavioral problems seen in patients with psychiatric and neurological disorders, including delusions, hallucinations, agitation, and anxiety.
He goes on to add, Why does this matter The current failed trial was in mild-to-moderate Alzheimers cases. But Pfizer ([5]NYSE:PFE) and Medivation are conducting two big trials in patients with moderate to severe Alzheimers Disease, who may have more severe behavioral problems. One of these trials uses the Neuropsychiatric Inventory as its primary goal; the other has it as a secondary goal. Dr. Schneider points out that the drug Dimebon bears some chemical similarity to various antidepressants and anti-psychotic drugs that improve behavior. It could be that the drug indeed does nothing to help memory at all directlybut does help improve behavior in severely demented patients.
If these two trials come out positive on the NPI, then the drug still may have a shot at getting approved.
Read the full report: [6]http://www.themarketfinancial.com/uncovering-the-hidden-opportunity- in-medivations-alzheimers-drug/125857 Latest Updates ___________________________________________________________________________ * $MDVN Phase III Alzheimer`s results expected any day * $OPTR Placed on high trade alert ahead of April/5 FDA Meeting [7] [8]Disclaimer | [9]Terms of Use | [10]Contact Us | [11]About Us | [12]Become an Author |
Related posts:
- Optimer Nears First CDI Treatment in 25 Years
- Buyout Rumours for Optimer Pharma
- Medivation’s Promising Prostate Cancer Treatment